ClinicalTrials.gg
Sign In

Lymphoma, T-Cell, Cutaneous clinical trials

The registry lists 554 studies for Lymphoma, T-Cell, Cutaneous across more than 10 countries. 63 are recruiting or about to start. 140 of them are mainly about Lymphoma, T-Cell, Cutaneous (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 2 narrower conditions too, such as Mycosis Fungoides: 635 studies, 81 open.

ClinicalTrials.gov finds 685 studies for Lymphoma, T-Cell, Cutaneous. How that becomes 554 here

This page counts the studies the registry files under Lymphoma, T-Cell, Cutaneous, and those it files under no condition that list Lymphoma, T-Cell, Cutaneousthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 685Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −80Filed under a narrower condition, counted on its own pageMycosis Fungoides 75 · Sezary Syndrome 5
  3. −6List Lymphoma, T-Cell, Cutaneous as a condition, but the registry did not file them under itMost often written as “Cutaneous T-Cell Lymphoma Refractory” (2), “Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease” (1), and “T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma” (1). The registry filed them under other conditions only, most often Lymphoma, T-Cell (3) and Recurrence (2).
  4. −45Match it another way14 name it in the title and 31 by a synonym or other text the search reads.
  5. 554The count on this page3 of them list Lymphoma, T-Cell, Cutaneous in their own words; the registry filed them under no condition.

Get an email when these change. Save the Lymphoma, T-Cell, Cutaneous studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
316
Terminated
94
Recruiting
44
Status unknown
34
Withdrawn
27
Not yet recruiting
18

Phase

Phase 1
227
Phase 2
204
Phase 3
38
Phase 4
8
Early Phase 1
6

Where

United States
434
France
37
Italy
35
Germany
32
United Kingdom
25
Spain
22

Who runs them

National Cancer Institute (NCI) (59) · Fred Hutchinson Cancer Center (33) · Northwestern University (21) · City of Hope Medical Center (20) · Memorial Sloan Kettering Cancer Center (15) · Case Comprehensive Cancer Center (14) · European Organisation for Research and Treatment of Cancer - EORTC (13) · National Institutes of Health Clinical Center (CC) (12)

What is being tested here

Drugs under test in Lymphoma, T-Cell, Cutaneous studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Mogamulizumab5111
Cyclophosphamide2122
Brentuximab Vedotin2211
Pembrolizumab206
Golidocitinib202
Ruxolitinib202
Bexarotene109
Durvalumab103
Methoxsalen103
Zeprumetostat102

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 8 open · JAK inhibitors 7 open · Immune checkpoint inhibitors 4 open · Alkylating agents 2 open · HDAC inhibitors 1 open

Coming up

2phase 3 studies under way
21studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 44 Lymphoma, T-Cell, Cutaneous studies recruiting now, 33 (75%) set no upper age limit and 6 (14%) stop at 75 or younger. 5 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (9%) take healthy volunteers.

Recruiting studies that take each age, of 44
AgeWomenMen
103 (7%)3 (7%)
1843 (98%)43 (98%)
3043 (98%)43 (98%)
4043 (98%)43 (98%)
5043 (98%)43 (98%)
6544 (100%)44 (100%)
7541 (93%)41 (93%)
8538 (86%)38 (86%)

Across all 554 studies, recruiting or not: 16% stop at 75 or younger and 8% at 65; 21% take children; 0% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, T-Cell, Cutaneous studies take

Of 47 phase 2 interventional studies under Lymphoma, T-Cell, Cutaneous, half reached primary completion within 64 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 155 mo42–80 · 45 studies—56 mo45–80 · 31 studies
Phase 1/263 mo32–88 · 16 studies——
Phase 264 mo36–97 · 47 studies—72 mo38–111 · 34 studies
Observational47 mo26–… · 23 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 554. Browse all 554 → or search them.